MedDataX Logo

6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA

NCT ID: NCT00360243

Last Updated: 2016-06-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1385 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360555

Sexual Dysfunctions, Psychological
COMPLETED PHASE3

6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

NCT00738738

Generalized Anxiety Disorder
WITHDRAWN PHASE3

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00735267

Generalized Anxiety Disorder
TERMINATED PHASE3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372

Generalized Anxiety Disorder
TERMINATED PHASE3

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008

Generalized Anxiety Disorder
TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexual Dysfunctions, Psychological

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

flibanserin 25 mg b.i.d

25 mg twice daily for 24 weeks

Group Type EXPERIMENTAL

flibanserin

Intervention Type DRUG

Experimental: flibanserin 25 mg b.i.d

flibanserin 50mg qhs

50 mg taken once daily at bedtime for 24 weeks

Group Type EXPERIMENTAL

flibanserin

Intervention Type DRUG

Experimental: flibanserin 50mg qhs

flibanserin 50mg b.i.d.

50 mg twice daily for 24 weeks

Group Type EXPERIMENTAL

flibanserin

Intervention Type DRUG

Experimental: flibanserin 50mg b.i.d.

placebo

twice daily for 24 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

flibanserin

Experimental: flibanserin 25 mg b.i.d

Intervention Type DRUG

flibanserin

Experimental: flibanserin 50mg qhs

Intervention Type DRUG

flibanserin

Experimental: flibanserin 50mg b.i.d.

Intervention Type DRUG

placebo

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women who are 18 years of age and older.
2. Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria.
3. Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress.
4. Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly.
5. Patients must be willing and able to use an electronic diary on a daily basis (e.g., have access to a working land line telephone for daily data transmissions).
6. At the Baseline Visit, patients must have complied with eDiary use adequately.
7. Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 1 year prior to the Screen Visit. The partner is expected to be physically present at least 50% of each month.
8. Patients must have used a medically acceptable method of contraception for at least 3 months before the Baseline Visit (Visit 2) and continue to use that medically acceptable method of contraception during the trial.
9. In the investigators opinion, patients must be reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them.
10. Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss their sexual functioning with the investigative staff.
11. Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Screen Visit.

Exclusion Criteria

1. Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening.
2. Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit.
3. Patients with a history of drug dependence or abuse within the past one year.
4. Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain.
5. Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin.
6. Patients who meet accepted diagnostic criteria for sexual disorders that would interfere with improvement in HSDD (sexual aversion, substance-induced sexual problems, urge to live as a man, etc.
7. Patients who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the patients response to treatment.
8. Patients who have entered the menopausal transition or menopause or have had a hysterectomy.
9. Patients with findings at the Screen Visit of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female organs.
10. Patients who are breast feeding or have breastfed within the last 6 months prior to the Baseline Visit.
11. Patients who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sprout Pharmaceuticals, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

511.70.01068 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

511.70.01040 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

511.70.01041 Boehringer Ingelheim Investigational Site

Tucson, Arizona, United States

Site Status

511.70.01003 Boehringer Ingelheim Investigational Site

Jonesboro, Arkansas, United States

Site Status

511.70.01070 Boehringer Ingelheim Investigational Site

Carmichael, California, United States

Site Status

511.70.01026 Boehringer Ingelheim Investigational Site

Redding, California, United States

Site Status

511.70.01015 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

511.70.01014 Boehringer Ingelheim Investigational Site

Stanford, California, United States

Site Status

511.70.01017 Boehringer Ingelheim Investigational Site

Tarzana, California, United States

Site Status

511.70.01072 Boehringer Ingelheim Investigational Site

Torrance, California, United States

Site Status

511.70.01078 Boehringer Ingelheim Investigational Site

Vista, California, United States

Site Status

511.70.01066 Boehringer Ingelheim Investigational Site

Walnut Creek, California, United States

Site Status

511.70.01064 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

511.70.01001 Boehringer Ingelheim Investigational Site

Wheat Ridge, Colorado, United States

Site Status

511.70.01050 Boehringer Ingelheim Investigational Site

Farmington, Connecticut, United States

Site Status

511.70.01006 Boehringer Ingelheim Investigational Site

Hartford, Connecticut, United States

Site Status

511.70.01055 Boehringer Ingelheim Investigational Site

New London, Connecticut, United States

Site Status

511.70.01024 Boehringer Ingelheim Investigational Site

Aventura, Florida, United States

Site Status

511.70.01056 Boehringer Ingelheim Investigational Site

Daytona Beach, Florida, United States

Site Status

511.70.01090 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

Site Status

511.70.01027 Boehringer Ingelheim Investigational Site

Gainesville, Florida, United States

Site Status

511.70.01062 Boehringer Ingelheim Investigational Site

New Port Richey, Florida, United States

Site Status

511.70.01043 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

511.70.01084 Boehringer Ingelheim Investigational Site

Pembroke Pines, Florida, United States

Site Status

511.70.01048 Boehringer Ingelheim Investigational Site

St. Petersburg, Florida, United States

Site Status

511.70.01042 Boehringer Ingelheim Investigational Site

Stuart, Florida, United States

Site Status

511.70.01063 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Site Status

511.70.01085 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Site Status

511.70.01086 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Site Status

511.70.01022 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

511.70.01057 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

511.70.01087 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

511.70.01052 Boehringer Ingelheim Investigational Site

Roswell, Georgia, United States

Site Status

511.70.01060 Boehringer Ingelheim Investigational Site

Champaign, Illinois, United States

Site Status

511.70.01058 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

511.70.01032 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

511.70.01018 Boehringer Ingelheim Investigational Site

Lexington, Kentucky, United States

Site Status

511.70.01007 Boehringer Ingelheim Investigational Site

Baton Rouge, Louisiana, United States

Site Status

511.70.01047 Boehringer Ingelheim Investigational Site

New Orleans, Louisiana, United States

Site Status

511.70.01079 Boehringer Ingelheim Investigational Site

New Orleans, Louisiana, United States

Site Status

511.70.01031 Boehringer Ingelheim Investigational Site

Saint Louis, Maryland, United States

Site Status

511.70.01011 Boehringer Ingelheim Investigational Site

Haverhill, Massachusetts, United States

Site Status

511.70.01028 Boehringer Ingelheim Investigational Site

Detroit, Michigan, United States

Site Status

511.70.01081 Boehringer Ingelheim Investigational Site

Detroit, Michigan, United States

Site Status

511.70.01082 Boehringer Ingelheim Investigational Site

Billings, Montana, United States

Site Status

511.70.01077 Boehringer Ingelheim Investigational Site

Moorestown, New Jersey, United States

Site Status

511.70.01019 Boehringer Ingelheim Investigational Site

Endwell, New York, United States

Site Status

511.70.01076 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

511.70.01025 Boehringer Ingelheim Investigational Site

Poughkeepsie, New York, United States

Site Status

511.70.01067 Boehringer Ingelheim Investigational Site

Purchase, New York, United States

Site Status

511.70.01016 Boehringer Ingelheim Investigational Site

Mount Airy, North Carolina, United States

Site Status

511.70.01044 Boehringer Ingelheim Investigational Site

Raleigh, North Carolina, United States

Site Status

511.70.01049 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

511.70.01089 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

511.70.01054 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

511.70.01075 Boehringer Ingelheim Investigational Site

Dayton, Ohio, United States

Site Status

511.70.01002 Boehringer Ingelheim Investigational Site

Mayfield Heights, Ohio, United States

Site Status

511.70.01065 Boehringer Ingelheim Investigational Site

Tulsa, Oklahoma, United States

Site Status

511.70.01083 Boehringer Ingelheim Investigational Site

Tulsa, Oklahoma, United States

Site Status

511.70.01036 Boehringer Ingelheim Investigational Site

Medford, Oregon, United States

Site Status

511.70.01004 Boehringer Ingelheim Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

511.70.01021 Boehringer Ingelheim Investigational Site

West Reading, Pennsylvania, United States

Site Status

511.70.01073 Boehringer Ingelheim Investigational Site

Warwick, Rhode Island, United States

Site Status

511.70.01023 Boehringer Ingelheim Investigational Site

Anderson, South Carolina, United States

Site Status

511.70.01035 Boehringer Ingelheim Investigational Site

Charleston, South Carolina, United States

Site Status

511.70.01008 Boehringer Ingelheim Investigational Site

Nasville, Tennessee, United States

Site Status

511.70.01020 Boehringer Ingelheim Investigational Site

Corpus Christi, Texas, United States

Site Status

511.70.01009 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

511.70.01030 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

511.70.01091 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

511.70.01013 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

511.70.01005 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

511.70.01061 Boehringer Ingelheim Investigational Site

Sandy City, Utah, United States

Site Status

511.70.01010 Boehringer Ingelheim Investigational Site

Burlington, Vermont, United States

Site Status

511.70.01012 Boehringer Ingelheim Investigational Site

Charlottesville, Virginia, United States

Site Status

511.70.01046 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

511.70.01029 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

511.70.01071 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

511.70.01033 Boehringer Ingelheim Investigational Site

Bellevue, Washington, United States

Site Status

511.70.01039 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

511.70.01069 Boehringer Ingelheim Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

511.70

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fluoxetine in Pediatric Body Dysmorphic Disorder
NCT00245635 COMPLETED PHASE4
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
NCT00658762 TERMINATED PHASE3
Fluoxetine for Anxious Children
NCT00000381 COMPLETED PHASE3
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834 ENROLLING_BY_INVITATION PHASE3
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
NCT00542685 COMPLETED PHASE3
Treatment of Obsessive-Compulsive Disorder
NCT00000373 COMPLETED PHASE4
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373 COMPLETED PHASE2/PHASE3
Psilocybin for Treatment of Obsessive Compulsive Disorder
NCT03300947 COMPLETED PHASE1
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
NCT00294346 COMPLETED PHASE2
Neuromodulation of the Dorsal Genital Nerve in Persistent Genital Arousal Disorder
NCT06790563 COMPLETED NA
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
NCT00808249 COMPLETED PHASE2
Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults
NCT03828149 COMPLETED PHASE1
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
NCT05103657 COMPLETED PHASE2
Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
NCT00632229 COMPLETED PHASE2
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039 RECRUITING NA
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
NCT03508700 COMPLETED PHASE3
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
NCT03033069 COMPLETED PHASE2
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
NCT00108836 COMPLETED PHASE2
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
NCT04693351 COMPLETED PHASE3
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
NCT00836069 TERMINATED PHASE3
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
NCT00616655 COMPLETED PHASE2
Duloxetine vs Placebo in the Treatment of General Anxiety
NCT00475969 COMPLETED PHASE3
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
NCT00725725 TERMINATED PHASE2
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
NCT05181995 TERMINATED PHASE2/PHASE3
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708 COMPLETED PHASE3